Aaron M. Tidman

Aaron M. Tidman

Mintz Levin

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Lessons from the OECD Foreign Bribery Report

In December 2014, the Organization for Cooperation and Economic Development (“OECD”) published its first-ever foreign bribery report, the most comprehensive study of foreign bribery cases around the globe that has ever been...more

3/3/2015

Goodyear’s Settlement with the SEC Emphasizes the Importance of FCPA Due Diligence in M&A Transactions and of Having a Robust...

On February 24, 2015, Goodyear Tire & Rubber Co. agreed to pay more than $16 million to settle charges that two of its subsidiaries allegedly paid $3.2 million in bribes that generated $14,122,535 in illicit profits. The SEC...more

2/26/2015 - Bribery Compliance Corruption Due Diligence FCPA Foreign Subsidiaries Goodyear Parent Corporation Risk Assessment SEC Subsidiaries

Mintz Levin Health Care Qui Tam Update - Recent Developments & Unsealed False Claims Act Cases: October 2014

Trends & Analysis - Between our last Qui Tam Update and the end of June, 65 health care–related qui tam cases were unsealed (28 in April, 18 in May, and 19 in June). Within those 65 cases...more

10/16/2014 - False Claims Act Healthcare Medicare Part D Pharmaceutical Pharmacies Prescription Drugs Qui Tam

Mintz Levin Health Care Qui Tam Update - Recent Developments & Unsealed False Claims Act (FCA) Cases: May 2014

Trends & Analysis: ..We have identified 58 health care–related qui tam cases that have been unsealed since our last Qui Tam Update. Of those, 33 cases were initiated after the start of 2012, with the remaining 25 cases...more

5/23/2014 - Clinical Laboratories Diagnostic Imaging Services FCA Healthcare Hospitals Laboratories Pharmacies Physicians Prescription Drugs Qui Tam

Subjective or Objective Truth? Supreme Court to Decide What Is an “Untrue” Statement of Opinion

On Monday, the U.S. Supreme Court granted certiorari in Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund (13-435), an appeal in which Omnicare has asked the Court to clarify the meaning of...more

3/6/2014 - Lying Material Misstatements Omnicare SCOTUS SEC Securities Act of 1933

Avoid the Anti-Corruption “Blacklist:” Chinese Agency Guidance

On March 1, 2014, Circular No. 50, which the Chinese National Health and Family Planning Commission (NHFPC) recently promulgated to regulate the conduct of pharmaceutical and medical device companies that do business in...more

3/5/2014 - Anti-Corruption Bribery China Healthcare Medical Devices Pharmaceutical

The SEC Speaks About FCPA

On February 21-22, 2014, the U.S. Securities and Exchange Commission held its annual “SEC Speaks” conference in Washington, D.C. On the first day of the conference, Kara Brockmeyer, Chief of the Foreign Corrupt Practices Act...more

2/26/2014 - Compliance Enforcement FCPA SEC

Mintz Levin Health Care Qui Tam Update -- Recent Developments and Unsealed Cases: September 2013

Trends and Analysis - ..We have identified 24 health care-related qui tam cases unsealed since last month’s Qui Tam Update. Of those, only 2 were filed in 2013. Nearly half were filed before 2011. ..Among the 24...more

9/26/2013 - False Claims Act FDA Healthcare Medical Devices NIH Pharmaceutical Qui Tam Sealed Records

Chinese Investigation of GlaxoSmithKlein Broadens as Details Emerge

In the weeks since our first post on the Chinese investigation of GlaxoSmithKlein (GSK) for alleged “widespread bribery of doctors” to induce the prescription of GSK’s drugs, more details have emerged about the bribery...more

7/25/2013 - Bribery China Compliance Conspiracies Detainment Ethics Foreign Nationals Foreign Official GlaxoSmithKline Investigations Pharmaceutical White Collar Crimes

Former ArthroCare CEO and CFO Charged with Securities Fraud, Wire Fraud

On July 16, 2013, the U.S. Department of Justice (DOJ) indicted Michael Baker and Michael Gluk, the former CEO and CFO, respectively, of ArthroCare Corp. – a Texas-based publicly traded surgical device company. Baker and...more

7/24/2013 - CEOs Distributors DOJ Fraud Fraud-on-the-Market Healthcare Investors Medical Devices SEC

Chinese Detain Pharmaceutical Company Managers in Economic Crime Probe

This week, reports have arisen that Chinese authorities in the cities of Shanghai, Beijing, and Changsha detained high-level GlaxoSmithKline (GSK) managers as part of an investigation into potential “economic crimes.” The...more

7/8/2013 - Bribery China Compliance DOJ FCPA GlaxoSmithKline Medical Devices Pharmaceutical SEC Whistleblowers

Comprehensive FCPA Guidance Provides a Roadmap for Companies to Reevaluate and Revise Their Compliance Policies By Paul E....

Originally published in The FCPA Report on November 28, 2012. On November 14, 2012, the DOJ and SEC jointly published “A Resource Guide to the U.S. Foreign Corrupt Practices Act” (Guidance), their long-awaited and...more

12/5/2012 - Compliance FCPA FCPA Resource Guide

Department of Justice and Securities and Exchange Commission Issue Highly Anticipated Foreign Corrupt Practice Act Guidance

On November 14th, the U.S. Department of Justice (DOJ) and U.S. Securities and Exchange Commission (SEC) jointly published “A Resource Guide to the U.S. Foreign Corrupt Practices Act” (the “Guide”), their long-awaited and...more

11/26/2012 - Compliance DOJ FCPA FCPA Resource Guide SEC

13 Results
|
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×